You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Developing novel technologies to monitor nociception and opioid administration during surgery and general anesthesia in order to minimize post-operative opioid requirementsSBC: PASCALL Systems, Incorporated Topic: NIDA
PROJECT SUMMARY In light of the opioid crises, minimizing postoperative pain and postoperative opioid requirements to reduce chronic opioid dependency among surgical patients have become major concerns for surgeons and anesthesiologists. Effective intraoperative nociception control can mitigate these concerns. Unfortunately, existing nociceptive monitoring tools use indicators that are inherently ...STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: GROW BIOMEDICINE LLC Topic: 300
Project Summary We have developed a candidate product that induces colon epithelial repair in ulcerative colitis (UC) models. UC comprises a major type of inflammatory bowel disease and is characterized by chronic and relapsing inflammation in the gastrointestinal (GI) tract. UC develops in the innermost mucosal layer of the distal GI tract in a continuous manner, usually starting at the rectum an ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: VENOVA TECHNOLOGIES, INC. Topic: NICHD
PROJECT SUMMARY The applicant, Venova Technologies, is a woman-led medical device startup company. Venova Technologies is applying for a Small Business Technology Transfer (STTR) Phase I grant to fund development towards technical milestones that will advance the commercial potential of our patent-pending non-hormonal contraceptive device. Half of pregnancies in the United States are unintended du ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
FASTT telehealth behavioral support service for caregivers of children with developmental delay or disabilitySBC: Special X, Inc Topic: NICHD
Project Abstract Over 7 million children in the U.S. receive support for a developmental delay or disability (DD). For caregivers of these children, behavior issues that often accompany their childandapos;s condition create high levels of stress leading to increased mental and physical health issues and impacts on caregiver-child interactions and family functioning. Although evidence-based practic ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Development and Pre-Clinical Testing of Antimicrobial PEKK/Silicon Nitride Trauma Plates with Carbon Fiber ReinforcementSBC: SINTX TECHNOLOGIES, INC. Topic: NIAMS
PROJECT SUMMARY—More than 2 million Americans are hospitalized each year with bone fractures, and many more undergo outpatient procedures for fracture reduction and fixation. Some injuries can be treated with closed reduction and splinting or casting to immobilize the bone during healing. However, at some sites, more than half of fractures require open reduction and internal fixation. Despite ad ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: Euler Scientific Topic: NGA20A001
Deep Convolutional Neural Networks (DCNNs) have become ubiquitous in the analysis of large datasets with geometric symmetries. These datasets are common in medicine, science, intelligence, autonomous driving and industry. While analysis based on DCNNs have proven powerful, uncertainty estimation for such analyses has required sophisticated empirical studies. This has negatively impacted the effect ...STTR Phase II 2022 Department of DefenseNational Geospatial-Intelligence Agency
Developing Active Stimulation and Monitoring Technologies to Optimize Pain and Nociception Management During Regional Anesthesia, General Anesthesia, and Post-Operative CareSBC: PASCALL Systems, Incorporated Topic: 106
Project Summary Surgery and acute post-operative pain are major contributors to persistent pain, chronic pain, and opioid dependence. Currently, there are no products on the market in the United States that can be used to monitor surgical nociception. Existing products use indicators that are susceptible to intraoperative influences such as blood loss, anesthetic drugs and antihypertensives. This ...STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
SBC: ELGIA THERAPEUTICS, INC. Topic: R
PROJECT SUMMARY/ABSTRACT The cysteine protease caspase-6 (Casp6) has been associated with neurodegenerative diseases for over fifteen years. In Alzheimer’s disease (AD), Casp6 is colocalized with amyloid plaques and tau tangles in human brain, and both human and animal model data indicate that activated Casp6 contributes to neuronal inflammation, neurodegeneration, and cleavage of proteins to to ...STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
SBC: Pioneer Neurotech Inc. Topic: 106
Project Summary / Abstract Nerve injuries arising from trauma, disease, or as a surgical necessity, lead most often to permanent loss of some or all functions mediated by the injured nerves. 50,000 peripheral nerve procedures are performed every year in the US, and 300,000 across Europe. After complete transection of a nerve, the optimal clinical procedure for nerve repair remains the surgical end ...STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
SBC: PARMEDICS, INC. Topic: 106
PROJECT SUMMARY Migraine affects over 36 million people in the US, particularly those of working age (18-55 years), negatively impacting workplace productivity and presenting an enormous healthcare burden. For almost half of those who suffer from migraine, current treatments fail to provide relief and have limited ability to reverse pain once it has started. The most effective medications either r ...STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health